TriangleNCT00784927 · OUTCOME
Progression-free Survival Time
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 1 year from registration.
What was measured
Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had disease progression at the time of their death. Progressive disease is defined as having one of the following: * The appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size. * At least a 50% increase from nadir in the sum of the product of the dimension (SPD) of any previously involved nodes. * At least a 50% increase in the longest diameter of any single previously identified node more than 1 cm in its short axis.
Groups in this outcome
Treatment
Participants with symptomatic untreated low grade NHL will be treated according to a 28 day schedule for up to a maximum of 12 consecutive cycles: 375 mg/m\^2 Rituximab IV on day 1. 20 mg Lenalidomide taken orally on days 1-21. 250 mg/m\^2 Cyclophosphamide orally on days 1, 8, 15. 40 mg Dexamethasone orally on days 1, 8, 15, 22.
| Group | Source count |
|---|---|
| Treatment | 33 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment | 38.3 | Not reported | 25.2 | NA | The 95% upper confidence limit was not reached. |
Complete source fields
- classes
- categories
- measurements
- comment
- The 95% upper confidence limit was not reached.
- group Id
- OG000
- lower Limit
- 25.2
- upper Limit
- NA
- value
- 38.3
- denoms
- counts
- group Id
- OG000
- value
- 33
- units
- Participants
- description
- Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had disease progression at the time of their death. Progressive disease is defined as having one of the following: * The appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size. * At least a 50% increase from nadir in the sum of the product of the dimension (SPD) of any previously involved nodes. * At least a 50% increase in the longest diameter of any single previously identified node more than 1 cm in its short axis.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants with symptomatic untreated low grade NHL will be treated according to a 28 day schedule for up to a maximum of 12 consecutive cycles: 375 mg/m\^2 Rituximab IV on day 1. 20 mg Lenalidomide taken orally on days 1-21. 250 mg/m\^2 Cyclophosphamide orally on days 1, 8, 15. 40 mg Dexamethasone orally on days 1, 8, 15, 22.
- id
- OG000
- title
- Treatment
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Up to 1 year from registration.
- title
- Progression-free Survival Time
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice